Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil

Emanuele Cozzani, Elisa Cinotti, Raffaella Felletti, David Pelucco, Alfredo Rebora, Aurora Parodi

Research output: Contribution to journalArticlepeer-review


Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50% of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalImmunopharmacology and Immunotoxicology
Issue number6
Publication statusPublished - Dec 2013


  • Autoimmune disease
  • Connective tissue disease
  • Corticosteroids
  • Lung involvement
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology


Dive into the research topics of 'Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil'. Together they form a unique fingerprint.

Cite this